题目内容 (请给出正确答案)
[主观题]

Which of the following statements about the effect of inflation on the capital-budgeting process is mostaccurate?

Zelda Haggerty was recently promoted to project manager at Verban Automation, a maker of industrial machinery. Haggerty’s first task as project manager is to analyze capital-spending proposals.

The first project under review is a proposal for a new factory. Verban wants to build the plant on land it already owns in India. Below are details included on a fact sheet regarding the factory project:

§ The initial outlay to the builder would be $85 million for the building. Verban would spend another $20 million on specialized equipment in the first year.

§ The factory would open up new markets for Verban’s products. Production should begin July 1 of the second year.

§ Verban’s tax rate is 34 percent.

§ Verban expects the factory to generate $205 million in annual sales starting in the third year, with half of that amount in the second year.

§ At the end of the sixth year, Verban expects the market value and the book value of the building to be worth $35 million, and the market value and the book value of the equipment to be worth $3.25 million.

§ Fixed operating costs are expected to be $65 million a year once the factory starts production.

§ Variable operating costs should be 40 percent of sales.

§ Verban uses straight-line depreciation.

§ New inventories are likely to boost working capital by $7.5 million in the first year of production.

§ Verban’s cost of capital for the factory project is 14.3 percent.

Verban’s chief of operations, Max Jenkins, attached a note containing some of his thoughts about the project. His comments are listed below:

§ Comment 1: “We spent $5 million up front on an exclusive, 10-year maintenance contract for all of our equipment in Asia two years ago, before an earlier project was canceled. Your budget should reflect that.”

§ Comment 2: “Some Asian clients are likely to switch over to the equipment from the new factory. They account for about $5 million a year in sales for the U.S. division. Your budget should reflect that.”

§ Comment 3: “I expect variable costs to take a one-time hit in Year 1, as we should plan for about $1.5 million in installation expense for the manufacturing equipment.”

§ Comment 4: “We bought the land allocated for this factory for $30 million in 1998. That money is long spent, so don’t worry about including it in the budget analysis.”

Haggerty is unimpressed with the advice she received from Jenkins and calculates cash flows and net present values using numbers from the fact sheet without taking any of the advice. She assumes all inflows and outflows take place at the end of the year.

Verban is also considering upgrading two smaller, outdated factories, projects for which the cost of capital is 14.3 percent. Both of the remodeled factories would have a three-year life and cash flows as follows:

Initial outlayYear 1Year 2Year 3

-$30 million$15 million$17 million$28 million

Verban is willing to pursue the new factory or the renovations, but not both projects. Haggerty decides which project makes the most sense and prepares models and recommendations for Verban’s executives. Haggerty is concerned that her budgeting calculations do not accurately affect inflation, so she attempts to tweak her models to reflect the 2.5 percent inflation expected annually over the next five years.

Part 3)

Which of the following statements about the effect of inflation on the capital-budgeting process is mostaccurate?

Statement 1: Inflation is reflected in the WACC, but future cash flows should still be adjusted when calculating the NPV.

Statement 2: Inflation will cause the WACC to decrease.

Statement 3: Inflation tends to exert upward pressure on the NPV.

Statement 4: Because the IRR does not depend on the WACC, inflation has no effect on it.

A) Statement 1 only.

B) Statements 2 and 3.

C) Statements 3 and 4.

D) Statements 1 and 2.

查看答案
如搜索结果不匹配,请 联系老师 获取答案
您可能会需要:
您的账号:,可能会需要:
您的账号:
发送账号密码至手机
发送
更多“Which of the following stateme…”相关的问题

第1题

In the last year of the new factory project, cash flows will be closest to:

Zelda Haggerty was recently promoted to project manager at Verban Automation, a maker of industrial machinery. Haggerty’s first task as project manager is to analyze capital-spending proposals.

The first project under review is a proposal for a new factory. Verban wants to build the plant on land it already owns in India. Below are details included on a fact sheet regarding the factory project:

§ The initial outlay to the builder would be $85 million for the building. Verban would spend another $20 million on specialized equipment in the first year.

§ The factory would open up new markets for Verban’s products. Production should begin July 1 of the second year.

§ Verban’s tax rate is 34 percent.

§ Verban expects the factory to generate $205 million in annual sales starting in the third year, with half of that amount in the second year.

§ At the end of the sixth year, Verban expects the market value and the book value of the building to be worth $35 million, and the market value and the book value of the equipment to be worth $3.25 million.

§ Fixed operating costs are expected to be $65 million a year once the factory starts production.

§ Variable operating costs should be 40 percent of sales.

§ Verban uses straight-line depreciation.

§ New inventories are likely to boost working capital by $7.5 million in the first year of production.

§ Verban’s cost of capital for the factory project is 14.3 percent.

Verban’s chief of operations, Max Jenkins, attached a note containing some of his thoughts about the project. His comments are listed below:

§ Comment 1: “We spent $5 million up front on an exclusive, 10-year maintenance contract for all of our equipment in Asia two years ago, before an earlier project was canceled. Your budget should reflect that.”

§ Comment 2: “Some Asian clients are likely to switch over to the equipment from the new factory. They account for about $5 million a year in sales for the U.S. division. Your budget should reflect that.”

§ Comment 3: “I expect variable costs to take a one-time hit in Year 1, as we should plan for about $1.5 million in installation expense for the manufacturing equipment.”

§ Comment 4: “We bought the land allocated for this factory for $30 million in 1998. That money is long spent, so don’t worry about including it in the budget analysis.”

Haggerty is unimpressed with the advice she received from Jenkins and calculates cash flows and net present values using numbers from the fact sheet without taking any of the advice. She assumes all inflows and outflows take place at the end of the year.

Verban is also considering upgrading two smaller, outdated factories, projects for which the cost of capital is 14.3 percent. Both of the remodeled factories would have a three-year life and cash flows as follows:

Initial outlayYear 1Year 2Year 3

-$30 million$15 million$17 million$28 million

Verban is willing to pursue the new factory or the renovations, but not both projects. Haggerty decides which project makes the most sense and prepares models and recommendations for Verban’s executives. Haggerty is concerned that her budgeting calculations do not accurately affect inflation, so she attempts to tweak her models to reflect the 2.5 percent inflation expected annually over the next five years.

Part 2)

In the last year of the new factory project, cash flows will be closest to:

A) $95.71 million.

B) $91.74 million.

C) $90.21 million.

D) $88.00 million.

点击查看答案

第2题

If Haggerty decides to properly allocate the maintenance, land-purchase, and equipment-installation

Zelda Haggerty was recently promoted to project manager at Verban Automation, a maker of industrial machinery. Haggerty’s first task as project manager is to analyze capital-spending proposals.

The first project under review is a proposal for a new factory. Verban wants to build the plant on land it already owns in India. Below are details included on a fact sheet regarding the factory project:

§ The initial outlay to the builder would be $85 million for the building. Verban would spend another $20 million on specialized equipment in the first year.

§ The factory would open up new markets for Verban’s products. Production should begin July 1 of the second year.

§ Verban’s tax rate is 34 percent.

§ Verban expects the factory to generate $205 million in annual sales starting in the third year, with half of that amount in the second year.

§ At the end of the sixth year, Verban expects the market value and the book value of the building to be worth $35 million, and the market value and the book value of the equipment to be worth $3.25 million.

§ Fixed operating costs are expected to be $65 million a year once the factory starts production.

§ Variable operating costs should be 40 percent of sales.

§ Verban uses straight-line depreciation.

§ New inventories are likely to boost working capital by $7.5 million in the first year of production.

§ Verban’s cost of capital for the factory project is 14.3 percent.

Verban’s chief of operations, Max Jenkins, attached a note containing some of his thoughts about the project. His comments are listed below:

§ Comment 1: “We spent $5 million up front on an exclusive, 10-year maintenance contract for all of our equipment in Asia two years ago, before an earlier project was canceled. Your budget should reflect that.”

§ Comment 2: “Some Asian clients are likely to switch over to the equipment from the new factory. They account for about $5 million a year in sales for the U.S. division. Your budget should reflect that.”

§ Comment 3: “I expect variable costs to take a one-time hit in Year 1, as we should plan for about $1.5 million in installation expense for the manufacturing equipment.”

§ Comment 4: “We bought the land allocated for this factory for $30 million in 1998. That money is long spent, so don’t worry about including it in the budget analysis.”

Haggerty is unimpressed with the advice she received from Jenkins and calculates cash flows and net present values using numbers from the fact sheet without taking any of the advice. She assumes all inflows and outflows take place at the end of the year.

Verban is also considering upgrading two smaller, outdated factories, projects for which the cost of capital is 14.3 percent. Both of the remodeled factories would have a three-year life and cash flows as follows:

Initial outlayYear 1Year 2Year 3

-$30 million$15 million$17 million$28 million

Verban is willing to pursue the new factory or the renovations, but not both projects. Haggerty decides which project makes the most sense and prepares models and recommendations for Verban’s executives. Haggerty is concerned that her budgeting calculations do not accurately affect inflation, so she attempts to tweak her models to reflect the 2.5 percent inflation expected annually over the next five years.

Part 1)

If Haggerty decides to properly allocate the maintenance, land-purchase, and equipment-installation expenses Jenkins claimed were connected with the new factory project, which of the followingnumbers on the capital-budgeting model will be least likely to change?

A) The accept/reject recommendation.

B) The initial outlay.

C) Year 4 depreciation.

D) Working capital.

点击查看答案

第3题

Regarding Klimecki’s and Alsen’s statements about the impact of the Beta Systems acquisition on

Beta Blocker Systems is a leading drug research and development facility. In the beginning of 2004, it was widely expected to receive approval to market a new beta blocker that it had developed internally. The new drug has significantly fewer side effects than the competing medications currently on the market.

Beta blockers are widely prescribed for a variety of medical conditions, including hypertension, angina, arrhythmias and congestive heart failure. They are also given to heart attack patients to prevent future heart attacks. Because of the widespread use of beta blockers, the market for them is large and their profitability is enormous.

Analysts put the value of the in-process research and development (R&D) for Beta Blocker Systems’ new drug at a whopping $500 million. The expected approval of the drug, and the consequent benefits to any parent companythat might own it, effectively put Beta Blocker Systems into play as an acquisition candidate.

Alphanumeric Research Laboratories, originally founded by Dr. Alka Klimecki, had grown to become a conglomerate with wide-ranging interests in nanotechnology, computer software, biotech, and other industries heavily reliant on research and development. Because of Alphanumeric’s diverse asset base, it was in a position to outbid other firms for Beta Blocker Systems. Alphanumeric Research Labs won the bidding war with an offer of $4.9 billion in Alphanumeric equity to buy out Beta Blocker shareholders. The transaction closed on June 30, 2004. (All balance sheet figures are calculated as of this date.) Alphanumeric recorded the acquisition as a purchase.

The buyout was a windfall for Beta Blocker Systems shareholders. Although the company had very valuable research facilities (shown on its balance sheet at $500 million below its fair market value), it had only $75 million in cash, not enough to fund the necessary development and marketing of the drug on its own without adversely impacting ongoing operations. It had also mismanaged its inventory, allowing much of it to become obsolete and forcing a write-down to its fair market value of $800 million.

The good news on Beta Blocker’s balance sheet was that it had virtually no debt. Owners’ equity stood at $3.335 billion, with the rest of the liabilities side of the balance sheet captured by a small level of current liabilities. However, this lack of debt seriously diluted the return to equity shareholders. Beta Blocker would have earned $40 million in net income in FY2004 (equally distributed throughout the year) if the acquisition had not taken place, providing a paltry return on owners’ equity.

Alphanumeric Research had an even more remarkable lack of leverage. Current liabilities of only $20 million paled in comparison with Alphanumeric’s stunning $4.530 billion in owners’ equity. Alphanumeric also managed its inventory much better than Beta Blocker Systems had. Its balance sheet showed only $500 million in inventory, all of which was current. In fact, Alphanumeric’s inventory had a fair market value 20 percent higher than book value.

Dr. Klimecki was pleased that the acquisition would further reduce Alphanumeric’s already miniscule total liabilities/owners’ equity ratio because of the additional equity issued to fund the purchase. The auditor, Nancy Alsen, added that the current assets/current liabilities ratio would also improve due to the write-up of inventory to fair market value.

Alphanumeric also had $50 million in cash. The remainder of Alphanumeric Systems’ assets were its research facilities, which had a fair market value of $4.2 billion, much larger than the $3 billion fair market value of Beta Blocker’s facilities.

Both Alphanumeric Research Laboratories and Beta Blocker Systems use fiscal years that match the calendar year and report in accordance with IAS standards. They amortize tangible assets over 20 years, and use the straight-line method for depreciation and amortization of both tangible and intangible assets.

Part 6)

Regarding Klimecki’s and Alsen’s statements about the impact of the Beta Systems acquisition on Alphanumeric’s consolidated balance sheet:

A)Klimecki’s statement is correct and Alsen’s statement is incorrect.

B)Klimecki’s statement is correct and Alsen’s statement is correct.

C)Klimecki’s statement is incorrect and Alsen’s statement is incorrect.

D)Klimecki’s statement is incorrect and Alsen’s statement is correct.

点击查看答案

第4题

What is the amount of goodwill (in millions) that Alphanumeric will record on its June 30, 2004 balance

Beta Blocker Systems is a leading drug research and development facility. In the beginning of 2004, it was widely expected to receive approval to market a new beta blocker that it had developed internally. The new drug has significantly fewer side effects than the competing medications currently on the market.

Beta blockers are widely prescribed for a variety of medical conditions, including hypertension, angina, arrhythmias and congestive heart failure. They are also given to heart attack patients to prevent future heart attacks. Because of the widespread use of beta blockers, the market for them is large and their profitability is enormous.

Analysts put the value of the in-process research and development (R&D) for Beta Blocker Systems’ new drug at a whopping $500 million. The expected approval of the drug, and the consequent benefits to any parent companythat might own it, effectively put Beta Blocker Systems into play as an acquisition candidate.

Alphanumeric Research Laboratories, originally founded by Dr. Alka Klimecki, had grown to become a conglomerate with wide-ranging interests in nanotechnology, computer software, biotech, and other industries heavily reliant on research and development. Because of Alphanumeric’s diverse asset base, it was in a position to outbid other firms for Beta Blocker Systems. Alphanumeric Research Labs won the bidding war with an offer of $4.9 billion in Alphanumeric equity to buy out Beta Blocker shareholders. The transaction closed on June 30, 2004. (All balance sheet figures are calculated as of this date.) Alphanumeric recorded the acquisition as a purchase.

The buyout was a windfall for Beta Blocker Systems shareholders. Although the company had very valuable research facilities (shown on its balance sheet at $500 million below its fair market value), it had only $75 million in cash, not enough to fund the necessary development and marketing of the drug on its own without adversely impacting ongoing operations. It had also mismanaged its inventory, allowing much of it to become obsolete and forcing a write-down to its fair market value of $800 million.

The good news on Beta Blocker’s balance sheet was that it had virtually no debt. Owners’ equity stood at $3.335 billion, with the rest of the liabilities side of the balance sheet captured by a small level of current liabilities. However, this lack of debt seriously diluted the return to equity shareholders. Beta Blocker would have earned $40 million in net income in FY2004 (equally distributed throughout the year) if the acquisition had not taken place, providing a paltry return on owners’ equity.

Alphanumeric Research had an even more remarkable lack of leverage. Current liabilities of only $20 million paled in comparison with Alphanumeric’s stunning $4.530 billion in owners’ equity. Alphanumeric also managed its inventory much better than Beta Blocker Systems had. Its balance sheet showed only $500 million in inventory, all of which was current. In fact, Alphanumeric’s inventory had a fair market value 20 percent higher than book value.

Dr. Klimecki was pleased that the acquisition would further reduce Alphanumeric’s already miniscule total liabilities/owners’ equity ratio because of the additional equity issued to fund the purchase. The auditor, Nancy Alsen, added that the current assets/current liabilities ratio would also improve due to the write-up of inventory to fair market value.

Alphanumeric also had $50 million in cash. The remainder of Alphanumeric Systems’ assets were its research facilities, which had a fair market value of $4.2 billion, much larger than the $3 billion fair market value of Beta Blocker’s facilities.

Both Alphanumeric Research Laboratories and Beta Blocker Systems use fiscal years that match the calendar year and report in accordance with IAS standards. They amortize tangible assets over 20 years, and use the straight-line method for depreciation and amortization of both tangible and intangible assets.

Part 1)

What is the amount of goodwill (in millions) that Alphanumeric will record on its June 30, 2004 balance sheet to reflect the acquisition of Beta Blocker Systems?

A)$25.

B)$40.

C)$125.

D)$565.

点击查看答案

第5题

Which statement about U.S. GAAP and IAS GAAP is FALSE?

Beta Blocker Systems is a leading drug research and development facility. In the beginning of 2004, it was widely expected to receive approval to market a new beta blocker that it had developed internally. The new drug has significantly fewer side effects than the competing medications currently on the market.

Beta blockers are widely prescribed for a variety of medical conditions, including hypertension, angina, arrhythmias and congestive heart failure. They are also given to heart attack patients to prevent future heart attacks. Because of the widespread use of beta blockers, the market for them is large and their profitability is enormous.

Analysts put the value of the in-process research and development (R&D) for Beta Blocker Systems’ new drug at a whopping $500 million. The expected approval of the drug, and the consequent benefits to any parent companythat might own it, effectively put Beta Blocker Systems into play as an acquisition candidate.

Alphanumeric Research Laboratories, originally founded by Dr. Alka Klimecki, had grown to become a conglomerate with wide-ranging interests in nanotechnology, computer software, biotech, and other industries heavily reliant on research and development. Because of Alphanumeric’s diverse asset base, it was in a position to outbid other firms for Beta Blocker Systems. Alphanumeric Research Labs won the bidding war with an offer of $4.9 billion in Alphanumeric equity to buy out Beta Blocker shareholders. The transaction closed on June 30, 2004. (All balance sheet figures are calculated as of this date.) Alphanumeric recorded the acquisition as a purchase.

The buyout was a windfall for Beta Blocker Systems shareholders. Although the company had very valuable research facilities (shown on its balance sheet at $500 million below its fair market value), it had only $75 million in cash, not enough to fund the necessary development and marketing of the drug on its own without adversely impacting ongoing operations. It had also mismanaged its inventory, allowing much of it to become obsolete and forcing a write-down to its fair market value of $800 million.

The good news on Beta Blocker’s balance sheet was that it had virtually no debt. Owners’ equity stood at $3.335 billion, with the rest of the liabilities side of the balance sheet captured by a small level of current liabilities. However, this lack of debt seriously diluted the return to equity shareholders. Beta Blocker would have earned $40 million in net income in FY2004 (equally distributed throughout the year) if the acquisition had not taken place, providing a paltry return on owners’ equity.

Alphanumeric Research had an even more remarkable lack of leverage. Current liabilities of only $20 million paled in comparison with Alphanumeric’s stunning $4.530 billion in owners’ equity. Alphanumeric also managed its inventory much better than Beta Blocker Systems had. Its balance sheet showed only $500 million in inventory, all of which was current. In fact, Alphanumeric’s inventory had a fair market value 20 percent higher than book value.

Dr. Klimecki was pleased that the acquisition would further reduce Alphanumeric’s already miniscule total liabilities/owners’ equity ratio because of the additional equity issued to fund the purchase. The auditor, Nancy Alsen, added that the current assets/current liabilities ratio would also improve due to the write-up of inventory to fair market value.

Alphanumeric also had $50 million in cash. The remainder of Alphanumeric Systems’ assets were its research facilities, which had a fair market value of $4.2 billion, much larger than the $3 billion fair market value of Beta Blocker’s facilities.

Both Alphanumeric Research Laboratories and Beta Blocker Systems use fiscal years that match the calendar year and report in accordance with IAS standards. They amortize tangible assets over 20 years, and use the straight-line method for depreciation and amortization of both tangible and intangible assets.

Part 5)

Which statement about U.S. GAAP and IAS GAAP is FALSE?

A)The current ratio of the consolidated firm under both accounting standards is typically higher than the pre-acquisition current ratio of either individual firm.

B)Both require capitalization of in-process R&D.

C)Both require write-up of assets to their fair market value.

D)Goodwill is tested annually for impairment under both methods.

点击查看答案

第6题

What is Beta Blockers’ contribution (in millions) to Alphanumeric’s FY04 net income (assuming they

Beta Blocker Systems is a leading drug research and development facility. In the beginning of 2004, it was widely expected to receive approval to market a new beta blocker that it had developed internally. The new drug has significantly fewer side effects than the competing medications currently on the market.

Beta blockers are widely prescribed for a variety of medical conditions, including hypertension, angina, arrhythmias and congestive heart failure. They are also given to heart attack patients to prevent future heart attacks. Because of the widespread use of beta blockers, the market for them is large and their profitability is enormous.

Analysts put the value of the in-process research and development (R&D) for Beta Blocker Systems’ new drug at a whopping $500 million. The expected approval of the drug, and the consequent benefits to any parent companythat might own it, effectively put Beta Blocker Systems into play as an acquisition candidate.

Alphanumeric Research Laboratories, originally founded by Dr. Alka Klimecki, had grown to become a conglomerate with wide-ranging interests in nanotechnology, computer software, biotech, and other industries heavily reliant on research and development. Because of Alphanumeric’s diverse asset base, it was in a position to outbid other firms for Beta Blocker Systems. Alphanumeric Research Labs won the bidding war with an offer of $4.9 billion in Alphanumeric equity to buy out Beta Blocker shareholders. The transaction closed on June 30, 2004. (All balance sheet figures are calculated as of this date.) Alphanumeric recorded the acquisition as a purchase.

The buyout was a windfall for Beta Blocker Systems shareholders. Although the company had very valuable research facilities (shown on its balance sheet at $500 million below its fair market value), it had only $75 million in cash, not enough to fund the necessary development and marketing of the drug on its own without adversely impacting ongoing operations. It had also mismanaged its inventory, allowing much of it to become obsolete and forcing a write-down to its fair market value of $800 million.

The good news on Beta Blocker’s balance sheet was that it had virtually no debt. Owners’ equity stood at $3.335 billion, with the rest of the liabilities side of the balance sheet captured by a small level of current liabilities. However, this lack of debt seriously diluted the return to equity shareholders. Beta Blocker would have earned $40 million in net income in FY2004 (equally distributed throughout the year) if the acquisition had not taken place, providing a paltry return on owners’ equity.

Alphanumeric Research had an even more remarkable lack of leverage. Current liabilities of only $20 million paled in comparison with Alphanumeric’s stunning $4.530 billion in owners’ equity. Alphanumeric also managed its inventory much better than Beta Blocker Systems had. Its balance sheet showed only $500 million in inventory, all of which was current. In fact, Alphanumeric’s inventory had a fair market value 20 percent higher than book value.

Dr. Klimecki was pleased that the acquisition would further reduce Alphanumeric’s already miniscule total liabilities/owners’ equity ratio because of the additional equity issued to fund the purchase. The auditor, Nancy Alsen, added that the current assets/current liabilities ratio would also improve due to the write-up of inventory to fair market value.

Alphanumeric also had $50 million in cash. The remainder of Alphanumeric Systems’ assets were its research facilities, which had a fair market value of $4.2 billion, much larger than the $3 billion fair market value of Beta Blocker’s facilities.

Both Alphanumeric Research Laboratories and Beta Blocker Systems use fiscal years that match the calendar year and report in accordance with IAS standards. They amortize tangible assets over 20 years, and use the straight-line method for depreciation and amortization of both tangible and intangible assets.

Part 4)

What is Beta Blockers’ contribution (in millions) to Alphanumeric’s FY04 net income (assuming they are both profitable and face a 40 percent tax rate)?

A)-$70.

B)$40.

C)$20.

D)-$103.90.

点击查看答案

第7题

What is the level of equity (in millions) on Alphanumeric’s consolidated balance sheet immediately

Beta Blocker Systems is a leading drug research and development facility. In the beginning of 2004, it was widely expected to receive approval to market a new beta blocker that it had developed internally. The new drug has significantly fewer side effects than the competing medications currently on the market.

Beta blockers are widely prescribed for a variety of medical conditions, including hypertension, angina, arrhythmias and congestive heart failure. They are also given to heart attack patients to prevent future heart attacks. Because of the widespread use of beta blockers, the market for them is large and their profitability is enormous.

Analysts put the value of the in-process research and development (R&D) for Beta Blocker Systems’ new drug at a whopping $500 million. The expected approval of the drug, and the consequent benefits to any parent companythat might own it, effectively put Beta Blocker Systems into play as an acquisition candidate.

Alphanumeric Research Laboratories, originally founded by Dr. Alka Klimecki, had grown to become a conglomerate with wide-ranging interests in nanotechnology, computer software, biotech, and other industries heavily reliant on research and development. Because of Alphanumeric’s diverse asset base, it was in a position to outbid other firms for Beta Blocker Systems. Alphanumeric Research Labs won the bidding war with an offer of $4.9 billion in Alphanumeric equity to buy out Beta Blocker shareholders. The transaction closed on June 30, 2004. (All balance sheet figures are calculated as of this date.) Alphanumeric recorded the acquisition as a purchase.

The buyout was a windfall for Beta Blocker Systems shareholders. Although the company had very valuable research facilities (shown on its balance sheet at $500 million below its fair market value), it had only $75 million in cash, not enough to fund the necessary development and marketing of the drug on its own without adversely impacting ongoing operations. It had also mismanaged its inventory, allowing much of it to become obsolete and forcing a write-down to its fair market value of $800 million.

The good news on Beta Blocker’s balance sheet was that it had virtually no debt. Owners’ equity stood at $3.335 billion, with the rest of the liabilities side of the balance sheet captured by a small level of current liabilities. However, this lack of debt seriously diluted the return to equity shareholders. Beta Blocker would have earned $40 million in net income in FY2004 (equally distributed throughout the year) if the acquisition had not taken place, providing a paltry return on owners’ equity.

Alphanumeric Research had an even more remarkable lack of leverage. Current liabilities of only $20 million paled in comparison with Alphanumeric’s stunning $4.530 billion in owners’ equity. Alphanumeric also managed its inventory much better than Beta Blocker Systems had. Its balance sheet showed only $500 million in inventory, all of which was current. In fact, Alphanumeric’s inventory had a fair market value 20 percent higher than book value.

Dr. Klimecki was pleased that the acquisition would further reduce Alphanumeric’s already miniscule total liabilities/owners’ equity ratio because of the additional equity issued to fund the purchase. The auditor, Nancy Alsen, added that the current assets/current liabilities ratio would also improve due to the write-up of inventory to fair market value.

Alphanumeric also had $50 million in cash. The remainder of Alphanumeric Systems’ assets were its research facilities, which had a fair market value of $4.2 billion, much larger than the $3 billion fair market value of Beta Blocker’s facilities.

Both Alphanumeric Research Laboratories and Beta Blocker Systems use fiscal years that match the calendar year and report in accordance with IAS standards. They amortize tangible assets over 20 years, and use the straight-line method for depreciation and amortization of both tangible and intangible assets.

Part 3)

What is the level of equity (in millions) on Alphanumeric’s consolidated balance sheet immediately following the acquisition?

A)$4,530.

B)$4,900.

C)$7,885.

D)$9,430.

点击查看答案

第8题

What is the book value of long-term assets (in millions)on Alphanumeric’s consolidated balance sheet

Beta Blocker Systems is a leading drug research and development facility. In the beginning of 2004, it was widely expected to receive approval to market a new beta blocker that it had developed internally. The new drug has significantly fewer side effects than the competing medications currently on the market.

Beta blockers are widely prescribed for a variety of medical conditions, including hypertension, angina, arrhythmias and congestive heart failure. They are also given to heart attack patients to prevent future heart attacks. Because of the widespread use of beta blockers, the market for them is large and their profitability is enormous.

Analysts put the value of the in-process research and development (R&D) for Beta Blocker Systems’ new drug at a whopping $500 million. The expected approval of the drug, and the consequent benefits to any parent companythat might own it, effectively put Beta Blocker Systems into play as an acquisition candidate.

Alphanumeric Research Laboratories, originally founded by Dr. Alka Klimecki, had grown to become a conglomerate with wide-ranging interests in nanotechnology, computer software, biotech, and other industries heavily reliant on research and development. Because of Alphanumeric’s diverse asset base, it was in a position to outbid other firms for Beta Blocker Systems. Alphanumeric Research Labs won the bidding war with an offer of $4.9 billion in Alphanumeric equity to buy out Beta Blocker shareholders. The transaction closed on June 30, 2004. (All balance sheet figures are calculated as of this date.) Alphanumeric recorded the acquisition as a purchase.

The buyout was a windfall for Beta Blocker Systems shareholders. Although the company had very valuable research facilities (shown on its balance sheet at $500 million below its fair market value), it had only $75 million in cash, not enough to fund the necessary development and marketing of the drug on its own without adversely impacting ongoing operations. It had also mismanaged its inventory, allowing much of it to become obsolete and forcing a write-down to its fair market value of $800 million.

The good news on Beta Blocker’s balance sheet was that it had virtually no debt. Owners’ equity stood at $3.335 billion, with the rest of the liabilities side of the balance sheet captured by a small level of current liabilities. However, this lack of debt seriously diluted the return to equity shareholders. Beta Blocker would have earned $40 million in net income in FY2004 (equally distributed throughout the year) if the acquisition had not taken place, providing a paltry return on owners’ equity.

Alphanumeric Research had an even more remarkable lack of leverage. Current liabilities of only $20 million paled in comparison with Alphanumeric’s stunning $4.530 billion in owners’ equity. Alphanumeric also managed its inventory much better than Beta Blocker Systems had. Its balance sheet showed only $500 million in inventory, all of which was current. In fact, Alphanumeric’s inventory had a fair market value 20 percent higher than book value.

Dr. Klimecki was pleased that the acquisition would further reduce Alphanumeric’s already miniscule total liabilities/owners’ equity ratio because of the additional equity issued to fund the purchase. The auditor, Nancy Alsen, added that the current assets/current liabilities ratio would also improve due to the write-up of inventory to fair market value.

Alphanumeric also had $50 million in cash. The remainder of Alphanumeric Systems’ assets were its research facilities, which had a fair market value of $4.2 billion, much larger than the $3 billion fair market value of Beta Blocker’s facilities.

Both Alphanumeric Research Laboratories and Beta Blocker Systems use fiscal years that match the calendar year and report in accordance with IAS standards. They amortize tangible assets over 20 years, and use the straight-line method for depreciation and amortization of both tangible and intangible assets.

Part 2)

What is the book value of long-term assets (in millions)on Alphanumeric’s consolidated balance sheet immediately after the acquisition?

A)$8,200.

B)$8,065.

C)$7,500.

D)$8,000.

点击查看答案

第9题

What is the amount of goodwill (in millions) that Alphanumeric will record on its June 30, 2004 balance

Beta Blocker Systems is a leading drug research and development facility. In the beginning of 2004, it was widely expected to receive approval to market a new beta blocker that it had developed internally. The new drug has significantly fewer side effects than the competing medications currently on the market.

Beta blockers are widely prescribed for a variety of medical conditions, including hypertension, angina, arrhythmias and congestive heart failure. They are also given to heart attack patients to prevent future heart attacks. Because of the widespread use of beta blockers, the market for them is large and their profitability is enormous.

Analysts put the value of the in-process research and development (R&D) for Beta Blocker Systems’ new drug at a whopping $500 million. The expected approval of the drug, and the consequent benefits to any parent companythat might own it, effectively put Beta Blocker Systems into play as an acquisition candidate.

Alphanumeric Research Laboratories, originally founded by Dr. Alka Klimecki, had grown to become a conglomerate with wide-ranging interests in nanotechnology, computer software, biotech, and other industries heavily reliant on research and development. Because of Alphanumeric’s diverse asset base, it was in a position to outbid other firms for Beta Blocker Systems. Alphanumeric Research Labs won the bidding war with an offer of $4.9 billion in Alphanumeric equity to buy out Beta Blocker shareholders. The transaction closed on June 30, 2004. (All balance sheet figures are calculated as of this date.) Alphanumeric recorded the acquisition as a purchase.

The buyout was a windfall for Beta Blocker Systems shareholders. Although the company had very valuable research facilities (shown on its balance sheet at $500 million below its fair market value), it had only $75 million in cash, not enough to fund the necessary development and marketing of the drug on its own without adversely impacting ongoing operations. It had also mismanaged its inventory, allowing much of it to become obsolete and forcing a write-down to its fair market value of $800 million.

The good news on Beta Blocker’s balance sheet was that it had virtually no debt. Owners’ equity stood at $3.335 billion, with the rest of the liabilities side of the balance sheet captured by a small level of current liabilities. However, this lack of debt seriously diluted the return to equity shareholders. Beta Blocker would have earned $40 million in net income in FY2004 (equally distributed throughout the year) if the acquisition had not taken place, providing a paltry return on owners’ equity.

Alphanumeric Research had an even more remarkable lack of leverage. Current liabilities of only $20 million paled in comparison with Alphanumeric’s stunning $4.530 billion in owners’ equity. Alphanumeric also managed its inventory much better than Beta Blocker Systems had. Its balance sheet showed only $500 million in inventory, all of which was current. In fact, Alphanumeric’s inventory had a fair market value 20 percent higher than book value.

Dr. Klimecki was pleased that the acquisition would further reduce Alphanumeric’s already miniscule total liabilities/owners’ equity ratio because of the additional equity issued to fund the purchase. The auditor, Nancy Alsen, added that the current assets/current liabilities ratio would also improve due to the write-up of inventory to fair market value.

Alphanumeric also had $50 million in cash. The remainder of Alphanumeric Systems’ assets were its research facilities, which had a fair market value of $4.2 billion, much larger than the $3 billion fair market value of Beta Blocker’s facilities.

Both Alphanumeric Research Laboratories and Beta Blocker Systems use fiscal years that match the calendar year and report in accordance with IAS standards. They amortize tangible assets over 20 years, and use the straight-line method for depreciation and amortization of both tangible and intangible assets.

Part 1)

What is the amount of goodwill (in millions) that Alphanumeric will record on its June 30, 2004 balance sheet to reflect the acquisition of Beta Blocker Systems?

A)$25.

B)$40.

C)$125.

D)$565.

点击查看答案

第10题

How would the auto industry most likely be affected by the business cycle? The industry is most likely to

Laura James is the head portfolio manager for National Fund, a U.S. based mutual fund with a well-respected track record. National’s primary focus is on large-cap domestic equities, and the fund has consistently posted highreturns relative to its peer group over the past seven years. Much of National’s recent success is from itsinvestments in the U.S. automobile industry, which have posted extraordinary returns due to a favorable economic scenario. Over the past seven years, the U.S. economy has been expanding, foreign competition has not met consumer expectations, and oil prices have remained low. These factors have contributed to an increase in market share for the domestic producers (at the expense of foreign competitors), and the result has been strong earnings for the top U.S. automakers.

Ford Motor Company, in particular, has enjoyed tremendous success in this environment. Ford has capitalized on the trend toward bigger vehicles, particularly sport utility vehicles (SUVs), and has outperformed the other domestic auto makers. Ford jumped on the SUV bandwagon early, and established its dominance. Other domestic auto makers followed, with foreign producers being the last to embrace the trend. Ford, has increased its market share in an increasingly competitive industry.

James is constantly reviewing economic forecasts and industry data in order to assess the expected performance of the investments in National’s portfolio. Due to changes in economic policy and recent volatility in energy prices, James now believes that current market conditions exhibit signs of contraction (recession). In addition, the automobile sector may be facing additional negative factors. In particular, James has concerns regarding the SUV segment of the automobile industry. Although she believes they will remain popular, she is concerned that the market may be reaching a point of saturation. In addition, volatile energy prices may dampen consumers’ enthusiasm for large vehicles. Lastly, foreign competitors have increased efforts toward the production of SUVs, thus “crowding” the market with many new models.

Part 6)

How would the auto industry most likely be affected by the business cycle? The industry is most likely to:

A)lead the business cycle.

B)not be affected.

C)perform. best during boom times.

D)perform. well during recovery.

点击查看答案
热门考试 全部 >
相关试卷 全部 >
账号:
你好,尊敬的上学吧用户
发送账号至手机
获取验证码
发送
温馨提示
该问题答案仅针对搜题卡用户开放,请点击购买搜题卡。
马上购买搜题卡
我已购买搜题卡, 登录账号 继续查看答案
重置密码
确认修改
谢谢您的反馈

您认为本题答案有误,我们将认真、仔细核查,
如果您知道正确答案,欢迎您来纠错

警告:系统检测到您的账号存在安全风险

为了保护您的账号安全,请在“上学吧”公众号进行验证,点击“官网服务”-“账号验证”后输入验证码“”完成验证,验证成功后方可继续查看答案!

微信搜一搜
上学吧
点击打开微信
警告:系统检测到您的账号存在安全风险
抱歉,您的账号因涉嫌违反上学吧购买须知被冻结。您可在“上学吧”微信公众号中的“官网服务”-“账号解封申请”申请解封,或联系客服
微信搜一搜
上学吧
点击打开微信